Supplemental Tables

Supplemental Table 1. Post-Workshop Ratings of Workshop Objectives by the Students - Classes 2001 to 2014

Supplemental Table 2. Mean Post-Workshop Ratings by the Students - Classes 2001 to 2014

Supplemental Table 3. Mean Percentage Outcome Measures Obtained from Students at 1 to 2 Years, 2 to 3 Years, and ≥ 5 Years after the Workshop

Supplemental Materials

S1. Teaching Schedule, Teaching Methods, and Evaluation Methods
S2. Typical Schedule for Workshop (with 2014 provided as an example)
S3. Student Affiliations (1996-2014)
S4. Faculty History (1996-2014)
S5. Thomson Reuters Evaluation

Supplemental Table 1: Post-Workshop Ratings of Workshop Objectives by the Students - Classes 2001 to 2014

[L]Includes Jr Biostatisticians and/or Corporate participants in analysis *A total of 99 students attended in 2009, but one student failed to receive an evaluation

	Percentages of participants at Workshops held from 2001 to 2014 indicating "Agree" or "Strongly Agree" with the listed statement														
Class	**2001**	**2002**	**2003**	**2004**	**2005**	**2006**	**2007**	**2008**	**2009**	**2010**	**2011**	**2012**	**2013**	**2014**	**Mean**
N total	109[L]	105[L]	107[L]	106[L]	104[L]	101	102[L]	102[L]	98*	101[L]	100[L]	100	97	99	**102**
Total Jr. Faculty or Fellow	100	100	102	100	101	101	101	100	99	100	99	100	97	99	**100**
Total Other Participant	9	5	5	6	3	0	1	2	0	1	1	0	0	0	**2**
Rate of return (%)	87%	87%	88%	89%	75%	98%	98%	98%	96%	96%	99%	94%	86%	97%	**97%**
Mean percentage ratings	-														
Workshop objectives	-														
In this workshop I was introduced to the principles of good clinical trial design	100	100	100	100	100	100	100	100	100	100	100	100	99	99	**99.9**
I was given the tools needed to conduct clinical trials that will yield clear results which investigators can use to proceed to the next level research	100	100	100	98	100	99	99	100	100	100	100	100	98	99	**99.5**
The workshop exposed me to the full spectrum of challenges in clinical research, from conventional antineoplastics to gene therapy	97	95	96	96	98	99	97	95	97	96	97	96	96	98	**96.6**
I was given adequate information in the protocol development sessions to develop a clinical trial protocol	99	98	99	98	99	98	98	99	100	99	98	98	96	99	**98.4**
My interest in conducting cancer clinical trials increased as a result of attending the workshop	99	97	98	96	97	96	99	99	100	99	97	99	100	96	**98.0**
The workshop increased my understanding of cancer and enabled me to understand new concept	95	94	96	97	91	100	95	97	95	95	97	97	96	95	**95.7**
I have made contacts with faculty members that will be useful in my future research	99	99	99	99	97	96	96	96	99	95	100	100	96	98	**97.8**
I have made contacts or networked with other participants	97	96	95	93	96	97	96	100	100	96	100	98	99	96	**97.1**

that will be useful in my future research															

Supplemental Table 2: Supplemental Table 2: Mean Post-Workshop Ratings by the Students - Classes 2001 to 2014

[L]Includes Jr Biostatisticians and/or Corporate participants in analysis

*A total of 99 students attended in 2009, but one student failed to receive an evaluation

Class	**2001**	**2002**	**2003**	**2004**	**2005**	**2006**	**2007**	**2008**	**2009**	**2010**	**2011**	**2012**	**2013**	**2014**	**Mean**
N total	109[L]	105[L]	107[L]	106[L]	104[L]	101	102[L]	102[L]	98*	101[L]	100	100	97	99	**102**
Total Jr. Faculty or Fellow	100	100	102	100	101	101	101	100	99	100	99	100	97	99	**100**
Total Other Participant Type	9	5	5	6	3	0	1	2	0	1	1	0	0	0	**2**
Rate of return (%)	87%	87%	88%	89%	75%	98%	98%	102[L]	96%	96%	99%	97%	86%	97%	**92%**
Didactic lectures															
Overall, the lecture addressed the stated instructional objectives	3.6	3.7	3.7	3.7	3.7	3.7	3.7	3.7	3.7	3.7	3.8	3.8	3.8	3.7	**3.7**
Overall, I learned a great deal from this lecture	3.4	3.5	3.6	3.6	3.5	3.6	3.5	3.5	3.5	3.6	3.7	3.7	3.6	3.6	**3.6**
The lecture will be helpful to me in designing/conducting clinical trials	3.2	3.4	3.5	3.6	3.5	3.6	3.5	3.4	3.5	3.6	3.6	3.7	3.6	3.6	**3.6**
The lecture was delivered in an effective manner	3.5	3.6	3.6	3.7	3.6	3.7	3.6	3.6	3.6	3.6	3.7	3.8	3.7	3.7	**3.7**
Protocol Development Groups															
In the protocol development group session, I received constructive feedback	3.8	3.8	3.8	3.8	3.8	3.9	3.8	3.8	3.9	3.8	3.8	3.8	3.9	3.9	**3.8**
I am leaving the workshop with a completed protocol	3.5	3.5	3.6	3.6	3.7	3.6	3.6	3.8	3.7	3.7	3.7	3.7	3.8	3.7	**3.7**
I expect to implement the trial described in my protocol within the next year	3.5	3.6	3.5	3.6	3.6	3.7	3.7	3.7	3.6	3.7	3.7	3.7	3.8	3.7	**3.7**
Faculty in Protocol Development Groups	3.8	3.8	3.8	3.8	3.9	3.8	3.9	3.7	3.9	3.8	3.9	3.8	3.9	3.9	**3.8**
Small Group Discussions															
Overall I learned a great deal from the discussion session	3.3	3.1	3.4	3.6	3.4	3.5	3.5	3.3	3.4	3.4	3.5	3.6	3.6	3.3	**3.5**
The discussion will be helpful to me in designing/conducting research protocols	3,2	3.3	3.5	3.6	3.4	3.5	3.5	3.3	3.4	3.4	3.6	3.6	3.6	3.3	**3.5**
The discussion session was conducted in an effective manner	3.4	3.5	3,2	3.7	3.5	3.6	3.5	3.3	3.5	3.5	3.5	3.6	3.6	3.4	**3.5**

Supplemental Table 3 - Mean Percentage Outcome Measures Obtained from Students at 1 to 2 Years, 2 to 3 Years, and ≥ 5 Years after the Workshop

	1-2 years surveys Class of 2001 to 2007	3-4 years surveys Class of 1998 to 2005	≥ 5 years surveys Class of 1996 to 2003
N return / N total	488 / 839	287 / 736	266 / 835
Rate of return (%)	58	38	32
Completion of medical training	73	96	99
Current position in:			
Academics/University	88	85	79
Activity main focus:			
1. Patient-oriented clinical research	49	53	60
2. Translational research	31	31	19
3. Basic research	3	2	5
4. Clinical practice	14	13	11
5. Other	2	1	5
Time spent on patient-oriented clinical research:			
1. Substantial	61	68	73
2. Some	31	29	21
3. Little	7	3	6
4. None	1	0	1
My participation in the workshop has been valuable to me in conducting clinical trials.			
If yes, why?	99	100	99
- Oriented me to principles of good clinical trial design	94	90	93
- Increased my understanding of the full spectrum of challenges in clinical cancer research	86	88	86
- Familiarized me with the process of approval/ implementation of clinical trials	74	71	76
- Raised my awareness of the importance of good clinical trial design for the benefit of cancer patients	80	61	81
- Other	7	8	11
My participation to the workshop has been valuable in advancing my career.			
If yes, why?	93	89	91
- Enhanced my clinical research productivity	63	61	68
- Stimulated me to continue my career in clinical cancer research	79	76	77
- Provided opportunities for networking	64	56	60
- Other	5	5	5
Have you maintained contact with any of the workshop faculty and/or fellow participants?			
If yes, why?	63	57	48
- Provided faculty mentoring	37	40	21
- Offered new prospects for research collaborations	41	48	44
- Opened up new job opportunities in clinical research	17	22	10
- Other	20	11	10
Status of workshop protocol/clinical trial			
- Submission to IRB	54	60	69
- Approval by IRB *	48	57	68
- Funding*	43	44	52
How many additional protocols have been submitted or approved by an IRB?			

Supplemental Table 3 - Mean Percentage Outcome Measures Obtained from Students at 1 to 2 Years, 2 to 3 Years, and ≥ 5 Years after the Workshop			
	1-2 years surveys Class of 2001 to 2007	3-4 years surveys Class of 1998 to 2005	≥ 5 years surveys Class of 1996 to 2003
1. 0	22	6	2
2. 1	26	10	2
3. 2	23	16	6
4. 3	16	17	14
5. 4	15	13	2
6. ≥ 5	8	39	49
How many have been implemented?			
1. 0	28	7	2
2. 1	29	15	5
3. 2	23	17	11
4. 3	11	16	7
5. 4	4	12	1
6. ≥ 5	6	33	50

Supplemental Material

S1. Teaching Schedule, Teaching Methods, and Evaluation Methods

The schedule was quite intense, with some participants referring to it as a "boot camp." (Refer to Supplemental Material S2 for a recent definitive example of the program.)

To impart the most knowledge during the workshop and have the students depart from the venue with an actionable protocol, the following teaching and evaluation methods were used.

Teaching methods

1. Didactic lectures – A total of 20 lectures including discussion was scheduled throughout the course.
2. Protocol Development Groups (PDG) – This was a particularly unique aspect of the workshop. Each student was assigned to a PDG for the week. Most PDGs comprised 8-10 students led by 2-3 clinical investigator faculty members, a biostatistician, and a patient advocate. The PDGs met at least 8 times throughout the workshop beginning on the first night with each student presenting his/her concept followed by initial feedback and questions from the faculty and fellow students. Throughout the workshop there were deadlines for deliverables, such as: (a) a formal concept sheet; (b) a draft protocol; (c) a patient informed consent form; and (d) a completed protocol suitable for submission to an IRB. Each document was reviewed and returned with in-person and written feedback from PDG mentors. The PDG sessions were intense, constructive, and highly interactive. Students often asked questions of each other and offered suggestions, and the faculty, by working together on the students' projects, had the opportunity to model the collaborative behavior needed for team science.
3. Other teaching methods – These included interactive Small Group Discussion Sessions covering a wide range of special topics such as biomarkers; selection of appropriate clinical trial endpoints; special populations; role play of an informed consent (along with a patient); Meet-the-Professor Sessions; career counseling sessions including advice on scientific writing, oral presentations, and grantsmanship; Special Interest Groups (e.g., immunology, radiation oncology, etc.); and mentoring, consultations, one-on-one meetings, and multiple other informal interactions at nearly every meal or break.

Evaluation methods

1. A pre-workshop test was given upon arrival on the first day (Saturday afternoon), consisting of 50-60 multiple-choice questions. This provided a baseline to determine how much didactic material had been mastered when compared to the same questions answered in a post-workshop exit test. These pre- and post-tests were mandatory for students and optional for junior biostatisticians and corporate attendees.
2. Daily and overall workshop evaluation questionnaires in which the participants (mandatory for students and optional for junior biostatisticians and corporate attendees) anonymously rated, on a scale from 1 (Strongly Disagree) to 4 (Strongly Agree), their level of satisfaction with the program, learning activities, and faculty.

3. Faculty ratings of students' achievement and progress in developing and completing their protocols during the Protocol Development Groups.
4. Intermediate and long-term surveys administered, respectively, 1 to 4 and 5 or more years after the workshop, to follow up on the students' academic position, level of activity in clinical research, and networking with workshop faculty and student colleagues. The very first survey was administered in 2002, and since then a total of seven surveys and eight workshops have been included in this review. Of the seven surveys, the first two were postal surveys, while the last five were administered online.
5. Comparisons by Thomson Reuters, through their data-mining method, of the numbers of publications, grants received, collaborations, and clinical trials implemented between 2002 and 2010 by those applicants who were selected versus those not selected for the workshop. The methodology for this study is outlined in S7.

S2. Typical Schedule for Workshop (2014 provided as an example)

Saturday, July 25

- Registration
- Administration of Pretest
- Welcome and Overview
- Protocol Development Group Session 1 / Dinner

Sunday, July 26

- Continental Breakfast
- Lecture Session 1
    - Statistical Considerations in Protocol Development: From Hypothesis to Analysis
    - Design and Analysis of Phase I Clinical Trials in Cancer Therapy
    - Novel Statistical Designs in Phase I Studies
- Lecture Session 2
    - Principles of Clinical Pharmacology
    - Phase II Trials
    - Novel Phase II Designs
- Protocol Development Group Session 2
- Lunch
- Office Hours 1: Protocol Related Questions
- Independent Study Time
- ASSIGNMENT DUE: PROTOCOL SYNOPSIS SHEETS
- Reception / Dinner

Monday, July 27

- Continental Breakfast
- Lecture Session 3
    - Incorporation of Biological Correlative Studies into Early Clinical Trials

    - Feasibility and Reproducibility in Biomarker Studies
    - Statistical Aspects of Correlative Studies
    - "Omics" Platform Considerations in Clinical Trials
- Lecture Session 4
    - Imaging in the Era of Targeted Therapy
    - Taking Your Product to Clinic
    - Barriers to Accrual and How to Overcome Them
- Protocol Development Group Session 3
- Lunch
- Small Group Discussion Sessions 1-2
    - Choosing Appropriate Clinical Endpoints
    - Imaging Endpoints in Clinical Trials
- Small Group Discussion Sessions 3-4
    - Inflammatory and Immunologic Biomarkers
    - Laboratory Correlates
- Independent Study Time / Dinner on Own
- ASSIGNMENT DUE: STATISTICAL SECTION

Tuesday, July 28

- Continental Breakfast
- Lecture Session 5
    - Navigating the Clinical Trials System and Clinical Trials in the Cooperative Groups
    - Quality of Life and Survivorship
- Break / Group Photo
- Protocol Development Group Session 4
- Lunch
- Small Group Discussion Sessions 5-7
    - First in Human Trials: Understanding the Regulatory Process
    - Written and Oral Research Presentations That Audiences Remember
    - Work-Life Balance (for Both Men and Women)
- Office Hours 2: Protocol Related Questions
- Independent Study Time / Dinner on Own
- ASSIGNMENT DUE: PROTOCOL DRAFT

Wednesday, July 29

- Continental Breakfast
- Lecture Session 6
    - Everything You Need to Know about Clinical Trial Ethics and Informed Consent: A Case History
    - You're in Charge: Investigator Responsibilities
- Lecture Session 7

    - Panel Discussion: Special Populations in Clinical Trials
- Protocol Development Group Session 5
- Lunch
- Special Interest Group and Career Sessions
    - Surgery and Surgery-related Specialties
    - Radiation Oncology
    - Pediatric Oncology
    - Becoming a Phase I Investigator
- Office Hours 3: Any Questions or Topics, including Career Related
- Independent Study Time / Dinner on Own
- Optional Session
    - Women in Academia
- ASSIGNMENT DUE: INFORMED CONSENT DOCUMENTS

Thursday, July 30

- Continental Breakfast
- Lecture Session 8
    - Career Development Opportunities: The Government Can Help
    - Successful Grantsmanship
- Protocol Development Group Session 6
- Administration of Postworkshop test
- Lunch
- Independent Study Time
- ASSIGNMENT DUE: FINAL PROTOCOL, INFORMED CONSENT DOCUMENTS, WORKSHOP EVALUATIONS
- Reception / Banquet / Dance

Friday, July 31

- Continental Breakfast

Departure

S3: Student Affiliations (1996-2014)

Abbott Biotherapeutics
Abramson Cancer Center of the University of Pennsylvania
Abraxis BioScience, Inc.
Aichi Cancer Center Research Institute
Alaska Native Tribal Health Consortium
Albany Medical College
Albert Einstein College of Medicine
Amgen, Inc.
Arizona Oncology
AstraZeneca
Atlantic Health Carol G. Simon Cancer Center
Aton Pharma, Inc.
Avera Cancer Institute
Barbara Ann Karmanos Cancer Institute
Barts & The London School of Med. & Dent.
Baylor College of Medicine
BC Cancer Agency
Belfast City Hospital
Beth Israel Deaconess Medical Center
Billings Clinic
Brigham & Women's Hospital
Bristol-Myers Squibb Co.
Brooke Army Medical Center
Brown University Medicine School
Cabrini Center for Cancer Care
California Pacific Medical Center
Cancer Center of North Carolina
Cancer Center of the Rockies
Cancer Research Center of Hawaii
Cancer Therapy & Research Center
Case Comprehensive Cancer Center
Case Western Reserve University
Cedars-Sinai Medical Center
Celgene Corporation
Centro Nacional de Investigaciones Oncológicas (CNIO)
Children's Hospital & Research Medical Center
Children's Hospital Colorado
Children's Hospital Los Angeles
Children's Hospital of Philadelphia
Children's National Medical Center
Chinese University of Hong Kong
Christian Medical College, Vellore
Christie Hospital
Cincinnati Children's Hospital Medical Center
City of Hope National Medical Center
Colorado Integrative Cancer Care
Columbia University Medical Center
Creighton University Medical Center
Cross Cancer Institute
Crozer-Keystone Health System
Daiichi-Sankyo, Inc.
Dana-Farber Cancer Institute
Dartmouth-Hitchcock Medical Center
Duke University Medical Center
East Tennessee State University
Eli Lilly and Company
Emory University Winship Cancer Institute
Erasmus Medical Center
Everett Clinic
Evergreen Hematology and Oncology
FDA-CDER
Flinders Medical Center
Fox Chase Cancer Center
Franklin Square Hospital Center
Fred Hutchinson Cancer Research Center
FUNDALEU
Garvan Institute of Medical Research
Genentech, Inc.
Georgetown Lombardi Comp. Cancer Center
Georgia Health Sciences University
German Cancer Research Center (DKFZ)
Good Samaritan Medical Center
H. Lee Moffitt Cancer Center & Res. Institute
Harbor-UCLA/City of Hope
Harvard Medical School
Harvard Medical School/Massachusetts General Hospital
Henry Ford Health System
Hillel Yaffe Medical Center
Hospital Geral de Fortaleza
Imclone Syst Int Gmbh
Indiana University
Indiana University Simon Cancer Center
Indiana University-Purdue University Indianapolis
Instituto Nacional de Cancerología
IU Health Goshen Center for Cancer Care
Jacobi Medical Center

Jamia Millia Islamia
Jennerex Biotherapeutics
John Wayne Cancer Institute
Johns Hopkins Kimmel Comp. Cancer Center
Johnson & Johnson Pharmaceutical R&D
Kaiser Permanente
King Abdulaziz Medical City
Levine Cancer Institute, Carolinas HealthCare System
Liverpool Hospital
Loma Linda University Medical Center
Louisiana State University Health Sciences Center
Loyola University Medical Center
LSU Feist-Weiller Cancer Center
Lucile Packard Children's Hospital
Magee-Womens Hospital
Maidstone General Hospital
Marshall University School of Medicine
Massachusetts General Hospital Cancer Center
Mayo Clinic
Mayo Clinic Arizona
Mayo Clinic Florida
McGill University
McMaster University Juravinski Cancer Center
Medical College of Wisconsin
Medical Oncology and Hematology Assoc.
Medical University of Gdansk
Medical University of SC Hollings Cancer Center
Medical University of South Carolina
Melbourne Blood Specialists
Memorial Sloan Kettering Cancer Center
Merck Research Laboratories
Michigan State University
Montefiore Medical Center
Mount Auburn Hospital
Mount Sinai Medical Center
Mundipharma International Ltd
National Cancer Center Hospital (Japan)
National Cancer Center Singapore
National Cancer Institute U.S.
National Cancer Institute Canada
National Cancer Institute Naples
Nemrock, Cairo University School of Medicine
Neurohealth Center
New England Medical Center
New York Medical College

New York University Langone Medical Center
New York University School of Medicine
Northwestern University Lurie Comp. Cancer Center
Norton Radiation Onc.
Novartis
NRG Oncology
Ochsner Medical Center
Ohio State University Comprehensive Cancer Center
OHSU Knight Cancer Institute
Oncology and Therapeutic Development
Oncology Center Antwerp (OCA)
Oregon State University
Ottawa Hospital Regional Cancer Center
Penn State University Hershey Medical Center
Pfizer Oncology
Pfizer, Inc.
PharmaMar S.A.
PharmaNet
PMK Consulting
PRA International
Providence Cancer Center
Queens Long Island Medical Group
R&D Systems, Inc.
Rainbow Babies & Children Hospital
Rockefeller University
Roswell Park Cancer Institute
Royal Brisbane Hospital
Rush University Medical Center
Rutgers R.W. Johnson Medical School
Saint Louis University
San Diego Healthcare System
Sanofi-Aventis Oncology
Sarah Cannon Research Institute
Scottsdale Healthcare/TGEN
Searle
Seattle Genetics, Inc.
Sinai Hospital
Southeast Gynecologic Oncology Assoc.
Spring Bioscience/Ventana
St. George Hospital
St. Jude Children's Research Hospital
St. Luke's Hospital & Health Network
St. Mary's Hospital
St. Michael's Hospital
Stanford Group Company
Stanford University School of Medicine

START
State University of New York
Stony Brook University
SUNY University Hospital & Medical Center
Sydney Cancer Center
Tata Cancer Hospital
TetraLogic Pharmaceuticals
Texas Children's Cancer Center
Texas Oncology, PA
Texas Tech University Health Sciences Center
TGen/Virginia G Piper Cancer Center
The Christie NHS Foundation Trust
The Cleveland Clinic Taussig Cancer Institute
The Rockwood Clinic
The Royal Marsden Hospital
Therakos Johnson & Johnson
Thomas Jefferson University Kimmel Cancer Center
Toledo Radiation Oncology, Inc.
Tulane University Medical Center
U.S. Army Medical Res. & Materiel Command
U.S. Oncology
UC Davis Cancer Center
UCLA David Geffen School of Medicine
UCLA Jonsson Comprehensive Cancer Center
UCSD
UCSD Moores Cancer Center
UCSF Comprehensive Cancer Center
UMDNJ-The Cancer Institute of New Jersey
UNC Lineberger Comp. Cancer Center
University Health Network Ontario Cancer Institute
University Health Network Princess Margaret Hospital
University Hospitals of Cleveland
University Hospitals/ Seidman Cancer Center
University Medical Center Groningen
University of Alabama Comp. Cancer Center
University of Arizona Cancer Center
University of British Columbia
University of California Irvine
University of California, Los Angeles
University of Chicago Medical Center
University of Cincinnati
University of Colorado Denver
University of Colorado/Children's Hospital Colorado
University of Florida
University of Illinois at Chicago
University of Iowa Holden Comp. Cancer Center
University of Kansas Medical Center
University of Kentucky Markey Cancer Center
University of Louisville Brown Cancer Center
University of Maryland Greenebaum Cancer Center
University of Miami
University of Michigan Comp. Cancer Center
University of Minnesota Masonic Cancer Center
University of Nebraska Medical Center
University of New Mexico - Albuquerque
University of North Carolina Chapel Hill
University of Nottingham
University of Oklahoma Health Sciences Center
University of Pennsylvania
University of Rochester Cancer Center
University of Rochester Medical Center
University of South Alabama Mitchell Cancer Institute
University of Toronto Hospital for Sick Children
University of Utah Huntsman Cancer Institute
University of Vermont College of Medicine
University of Virginia
University of Washington
University of Washington Medical Center
University of Western Ontario
University of Wisconsin Comprehensive Cancer Center
University Surgical Associates
UPMC Cancer Center
USC Keck School of Medicine
USC Children's Hospital Los Angeles
USC Norris Comprehensive Cancer Center
UT Health Science Center at Houston
UT Health Science Center at San Antonio
UT MD Anderson Cancer Center
UT Medical Branch
UT Southwestern Medical Center
VA Medical Center Albany
Vall d'Hebron University Hospital
Vanderbilt-Ingram Cancer Center
Vermont Cancer Center
Virginia Commonwealth University
VU University Medical Center
Wake Forest University Baptist Medical Center
Walter Reed Army Medical Center
Washington Cancer Institute

Washington Hospital Center
Washington University Siteman Cancer Center
Waterford Regional Hospital
Weill Cornell Medical College of Cornell University
West Virginia University Randolph Cancer Center
Westmead Hospital
Weston Park Hospital
Wilford Hall Medical Center

William Beaumont Hospital
Women & Infants Hospital
Yale Cancer Center
Yale Oncology Fellowship Program
Yale-New Haven Hospital
Yonsei University Cancer Center

S4: Faculty History (1996-2014)
(Affiliations listed were current during the years of service)

James L. Abbruzzese, MD, FACP (1999-2006)
The University of Texas MD Anderson Cancer Center
Specialty Preferences: Clinical study and treatment of pancreatic cancer

Alex A. Adjei, MD, PhD (2004-2008)
Roswell Park Cancer Institute
State University of New York at Buffalo
Specialty Preferences: Phase I clinical trials; biomarkers; lung cancer; pharmacogenetics; clinical trials in special populations

David S. Alberts, MD (1996-1998)
University of Arizona Cancer Center
Specialty Preferences: Clinical trials in cancer prevention, biomarkers, chemoprevention

James R. Anderson, PhD. (1998, 2000)
University of Nebraska Medical Center
Specialty Preferences: Study design, biostatistics

Kenneth C. Anderson, MD (2007)
Dana-Farber Cancer Institute
Harvard Medical School
Specialty Preferences: Multiple myeloma; drug development; translational research

Karen H. Antman, MD (2003)
Boston University, School of Medicine
Specialty Preferences: Breast cancer; mesotheliomas; sarcomas

Jean-Pierre Armand, MD (1997-1998)
Institut de Cancérologie Gustave Roussy
Specialty Preferences: Early drug development; Phase I and II clinical trials; novel anticancer agents

Carlos L. Arteaga, MD (2005)
Vanderbilt-Ingram Cancer Center Breast Cancer Program
Vanderbilt University School of Medicine
Vanderbilt-Ingram Comprehensive Cancer Center
Specialty Preferences: Oncogenes and breast tumor initiation and progression; targeted therapies and biomarkers of drug action and resistance; clinical trials in breast cancer

Steven D. Averbuch, MD (2002- 2003)
S.D. Averbuch Consulting, LLC
Specialty Preferences: Biochemical modulators of therapy and toxicity; biomarkers; clinical trials in solid tumors; diagnostic techniques

Rochelle Bagatell, MD (2004-2008)
University of Arizona
Specialty Preferences: Neuroblastoma; early phase clinical trials in pediatrics; pediatric cooperative group studies

Joseph S. Bailes, MD (2006)
US Oncology
Specialty Preferences: Clinical practice; legislation, public policy, and advocacy

Dean F. Bajorin, MD (2006)
Memorial Sloan Kettering Cancer Center
Specialty Preferences: Bladder cancer; testicular cancer; renal cell cancer; prostate cancer

Charles M. Balch, MD (2000-2005)
American Society of Clinical Oncology
Johns Hopkins Medical Institutions
Specialty Preferences: Melanoma and breast cancer research; tumor immunology and human T lymphocyte differentiation

Lodovico Balducci, MD (2001-2003)
Moffitt Cancer Center
Specialty Preferences: Geriatric oncology; clinical trials in solid tumors; combined modalities of therapy

Gary J. Becker, MD (2005)
National Cancer Institute
Specialty Preferences: Vascular and interventional radiology

Stacey L. Berg, MD (2010-2014)
Texas Children's Cancer Center
Specialty Preferences: Pediatric oncology; biomedical ethics; palliative care

Monica M. Bertagnolli, MD (2006-2007)
Harvard University Medical School
Dana-Farber Cancer Institute
Brigham and Women's Hospital
Specialty Preferences: Surgical oncology; colorectal cancer pathogenesis; familial colon cancer; colorectal cancer prevention trials

Michael R. Bishop, MD (2011-2013)
University of Chicago, Department of Medicine
Specialty Preferences: Clinical transplantation therapy; novel clinical trials in allogeneic and autologous stem cell transplantation; B cell malignancies, T cell reconstitution

A. William Blackstock, MD, (2007-2012)
Wake Forest University School of Medicine
Specialty Preferences: Phase I/II chemoradiation trial design; preclinical chemoradiation trials; chemoradiation translational studies

Douglas W. Blayney, MD (2008)
Stanford Cancer Center
Specialty Preferences: Oncology; quality of life; informatics; hematological malignancies

W. Archie Bleyer, MD (1998, 2000)
The University of Texas MD Anderson Cancer Center
Specialty Preferences: Clinical trials in leukemias and lymphomas; clinical trials in solid tumors; combined modalities of therapy; drug delivery systems; drug evaluation methodology

James M. Boyett, PhD (1998, 2000, 2002)
St. Jude Children's Research Hospital
Specialty Preferences: Biostatistics; pediatric brain tumors

Thomas M. Braun, PhD, MS, BBA (2013-2014)
University of Michigan School of Public Health
Specialty Preferences: Adaptive phase I trial designs in oncology; multivariate longitudinal modeling of periodontal outcomes

Otis W. Brawley, MD (1996-1998)
National Cancer Institute
Specialty Preferences: Clinical trials; breast cancer; epidemiology

Dean E. Brenner, MD (2000)
University of Michigan
Specialty Preferences: Pharmacodynamics of anticancer drugs; chemoprevention

Diane A. Bronzert , MD (1998)
National Cancer Institute
Specialty Preferences: Brain and breast cancers; drug and multidrug resistance; phase I-II studies

Paul A. Bunn, MD (2002)
University of Colorado
Specialty Preferences: Lung and Thoracic Cancers

Gregory Burke (1996, 1998)
Novartis
Specialty Preferences: Drug development

Michael A. Caligiuri, MD (2003-2007)
The Ohio State University
Specialty Preferences: Immunology; leukemia and lymphoma; Epstein-Barr virus

Rick J. Chappell, PhD (2007-2014)
University of Wisconsin
Specialty Preferences: Statistics; goals and aims (primary/secondary); power/sample size calculations; analysis plans; noninferiority trials; radiation oncology; phase I clinical trial design

Michaele C. Christian, MD (2003)
National Institutes of Health
Specialty Preferences: NCI Clinical Trials Monitoring Branch

Edward Chu, MD (2014)
University of Pittsburgh School of Medicine
Specialty Preferences: Clinical trials/biostatistics/epidemiology; gastrointestinal cancer; general oncology; cancer education

Gary M. Clark, PhD (1996-2001, 2010-2011)
Array BioPharma, Inc.
Specialty Preferences: Identification and evaluation of prognostic and predictive biomarkers for breast cancer, lung cancer, and other solid tumors; design and analysis of phase I, II, and III clinical trials of targeted therapies

Neil J. Clendeninn, MD, PhD (2004-2008)
CANAID, Inc.
Specialty Preferences: Clinical drug development; clinical pharmacology; regulatory issues; industry-biotech/pharma

Laura Cleveland (2008, 2010-2013)
The Ohio State University
Specialty Preferences: Patient advocacy; trial design; patient accrual issues; regulatory mandates and informed consent

Jerry M. Collins, PhD (1996-1997)
National Cancer Institute
Specialty Preferences: Clinical pharmacology

Deborah Collyar (2002)
Patient Advocates in Research (PAIR)
Specialty Preferences: Patient advocacy

Charles A. Coltman, MD (1996-1998, 2000-2001)
The University of Texas Health Science Center. at San Antonio
Specialty Preferences: Breast cancer; combined modalities of therapy; drug evaluation

John J. Crowley, PhD (1996-1998, 2000)
Cancer Research and Biostatistics
Specialty Preferences: Biostatistics

Ramzi N. Dagher, MD (2003)
Pfizer, Inc.
Specialty Preferences: Sarcomas and soft tissue cancers; clinical trials in solid tumors; combined modalities of therapy; study design and methods

Otilia Dalesio, M.Sc (1998, 2000, 2003)
Netherlands Cancer Institute
Specialty Preferences: Multicenter trials; lung and colorectal cancers

Mary B. Daly, MD, PhD, FACP (2002)
Fox Chase Cancer Center
Specialty Preferences: Clinical genetics; breast cancer; risk assessment; chemoprevention research; family risk assessment and genetic testing; epidemiology; gynecologic cancers

Gwen Darien (2003-2005)
American Association for Cancer Research
Specialty Preferences: Patient advocacy and engagement; community engagement in genomics

Christopher K. Daugherty, MD (1998, 2000)
University of Chicago
Specialty Preferences: Ethical issues in cancer care and clinical research; stem cell transplantation; leukemia

Angela M. Davies, MD, FRCP(C) (2009-2010)
OSI Pharmaceuticals
Specialty Preferences: Medical oncology; small molecule therapeutics; lung cancer

Thomas Davis, MD (1997)
Celldex Therapeutics
Specialty Preferences: Drug development; immune-oncology

Angelo M. De Marzo, MD, PhD (2009-2014)
Johns Hopkins University School of Medicine
Specialty Preferences: Pathology; prostate cancer; biomarkers

Patricia Delaney (2001)
U.S. Food and Drug Administration
Specialty Preferences: Public education about and inclusion of cancer survivors; cancer in drug development

Peggy Devine (2007)
University of California San Francisco
Specialty Preferences: Writing a quality consent form; retention strategies; accrual strategies; community/minority outreach

Mary L. (Nora) Disis, MD (2001-2004, 2007-2012)
Washington School of Medicine
Fred Hutchinson Cancer Research Center
Specialty Preferences: Breast and ovarian cancer; tumor immunology; translational oncology; biomarkers

Chaitanya R. Divgi, MD (2011-2012)
Columbia University
Specialty Preferences: Renal cancer; ovarian cancer; antibodies in cancer imaging and therapy; PET; radiochemistry

Everett D. Dodson (2013-2014)
Howard University Cancer Center
Specialty Preferences: Colon cancer; prostate cancer; patient and research subject advocacy

Afshin Dowlati, MD (2013-2014)
Case Western Reserve University
Specialty Preferences: Experimental therapeutics; hematology/oncology; lung cancer; phase I clinical trials; thoracic cancer

Brian J. Druker, MD (2004)
OHSU Knight Cancer Institute
Specialty Preferences: Leukemia; precision medicine; targeted therapies

John R. Durant, MD (1997-1998)
American Society of Clinical Oncology
Specialty Preferences: Translational and clinical research; combination chemotherapy

Janice J. Dutcher, MD (1996-1998, 2000-2002)
St. Luke's-Roosevelt Hospital Center.
Specialty Preferences: Clinical trials; renal cell cancer; immunotherapy

S. Gail Eckhardt, MD (2000-2003, 2006-2014)
University of Colorado Cancer Center
Specialty Preferences: Early clinical trials; colorectal cancer research; preclinical and clinical development of molecularly targeted compounds; melanoma; predictive biomarkers

Merrill J. Egorin, MD, FACP (1996-2004, 2007-2009)
University of Pittsburgh School of Medicine
Specialty Preferences: Clinical pharmacology; phase I trials; pharmacokinetics; cancer in the elderly

Lawrence Einhorn, MD (2000)
Indiana University School of Medicine
Specialty Preferences: clinical trials and supportive care for lung and testicular cancers

Lee M. Ellis, MD (2007-2012)
The University of Texas MD Anderson Cancer Center
Specialty Preferences: Biomarkers; targeted therapies; angiogenesis; surgical oncology: GI cancer

Ezekiel J. Emanuel, MD (2001-2004)
National Institutes of Health
Specialty Preferences: Medical ethics; breast oncology

Charis Eng, MD, PhD (2001)
The Cleveland Clinic
Specialty Preferences: Genomic medicine

Elihu H. Estey, MD (2002)
Fred Hutchinson Cancer Research Center
Specialty Preferences: Trial design that can monitor multiple outcomes; acute myeloid leukemia

Martine Extermann, MD, PhD (2006)
University of South Florida
H. Lee Moffitt Cancer Center
Specialty Preferences: Geriatric oncology; comprehensive assessment/multivariate analyses/outcome; breast cancer; AML in the elderly (clinical); comorbidity; decision analysis

John M. Falleta, MD (2003)
Duke University Medical Center
Specialty Preferences: Pediatric oncology

Ann T. Farrell, MD (2004-2005)
U. S. Food and Drug Administration
Specialty Preferences: FDA regulations; endpoints; hematologic malignancies; trial design

David W. Feigal, MD (1996-1997)
U. S. Food and Drug Administration
Specialty Preferences: Drug development

Ellen G. Feigal, MD 1997)
California Institute for Regenerative Medicine
Specialty Preferences: Clinical study design; drug development

Scott Z. Fields, MD (2004-2005)
EISAI
Columbia University College of Physicians and Surgeons
NY Presbyterian Hospital
Specialty Preferences: Hematology and oncology disorders

Robert A. Figlin, MD (1998, 2000)
Cedars-Sinai Medical Center
Specialty Preferences: Kidney cancers; translational research; clinical trials

Lawrence H. Fong, MD (2010-2014)
University of California San Francisco
Specialty Preferences: Prostate cancer; cancer immunotherapy; kidney cancer; melanoma; immunologic biomarkers

Margaret Foti, PhD, MD (hc) (1998-2014)
American Association for Cancer Research (AACR)
Specialty Preferences: Nonprofit association management; scholarly publishing; scientific communications; science policy and government affairs; foundation support; research administration

Wilbur A. Franklin, MD (2006-2008)
University of Colorado Denver Health Sciences Center
Specialty Preferences: Pathobiology; biomarkers; lung cancer

Patricia A. Ganz, MD (2002, 2005)
UCLA Schools of Medicine and Public Health
Jonsson Comprehensive Cancer Center
Specialty Preferences: Cancer survivorship; late effects of cancer treatment; care quality of cancer patients; cancers in the elderly

Elizabeth Garrett-Mayer, PhD (2002-2004, 2006-2014)
Medical University of South Carolina Hollings Cancer Center
Specialty Preferences: Biostatistics; predictive models; phase I and phase II study designs; power and sample size

Robert A. Gatenby, MD (2006-2007)
H. Lee Moffitt Cancer Center & Research Institute
Specialty Preferences: Evolutionary dynamics in cancer and cancer drug resistance

Constantine A. Gatsonis, PhD (2005)
Brown University
Specialty Preferences: Development of statistical methods for diagnostic tests and biomarker evaluation; design and analysis of clinical trials of diagnostic and screening modalities

Stephen George, PhD (1997-1998, 2000, 2003)
Duke University Medical Center
Specialty Preferences: Statistical issues related to the design, conduct, and analysis of clinical trials

Stanton L. Gerson, MD (2003)
Case Comprehensive Cancer Center
Specialty Preferences: DNA repair and stem cell therapy

Jorge Gomez, MD, PhD (2003)
University of Arizona Health Sciences Center
Specialty Preferences: Community-based research; cancer health disparities.

Mithat Gönen, PhD (2007-2012)
Memorial Sloan Kettering Cancer Center
Specialty Preferences: Clinical trials with imaging endpoints; surgical oncology clinical trials; staging and prognosis; general biostatistics

Steven Goodman, MD, PhD (1998)
Johns Hopkins University
Specialty Preferences: Reproducibility and efficiency of biomedical research

David J. Gordon, MD (2000)
University of Iowa
Specialty Preferences: Ewing sarcoma; pediatric oncology

Gary B. Gordon, MD, PhD (2000)
Ayala Pharmaceuticals
Specialty Preferences: Drug development

Lester S. Gorelic, PhD (1998, 2001-2009)
National Cancer Institute
Specialty Preferences: Support for cancer research training and career development

Sylvan B. Green, MD (1999-2005)
University of Arizona
Arizona Cancer Center
Specialty Preferences: Design and analysis of clinical trials; prevention trials, epidemiologic studies; biostatistical and computer methodology application

Charles K. Grieshaber (1996)
Oncology Research & Regulatory Consulting Associates (ORRCA), Inc.
Specialty Preferences: Pharmacokinetics; drug evaluation

Louise B. Grochow, MD (2000-2002)
AstraZeneca
Specialty Preferences: Drug development

Susan G. Groshen, PhD (2001-2004, 2006)
University of Southern California Keck School of Medicine
USC/Norris Comprehensive Cancer Center

Specialty Preferences: Biostatistics; urology/bladder cancer; phase I trials

Stuart A. Grossman, MD (2008-2014)
Johns Hopkins University
Specialty Preferences: Primary brain tumors; CNS metastases; cancer pain; clinical trial design and conduct

Stephen J. Gwyther, MD (2003)
East Surrey Hospital
Specialty Preferences: Clinical radiology, imaging

Stephen M. Hahn, MD (2004-2008)
University of Pennsylvania Hospital
Specialty Preferences: Radiation oncology; non-small cell lung cancer; combined chemoradiotherapy; prostate cancer

Lyndsay N. Harris, MD (2013-2014)
Case Western Reserve University
Specialty Preferences: Breast cancer; cancer prevention; psychosocial issues/psychiatry; tumor biology/molecular biology/growth factors/cytokines

Ernest T. Hawk, MD, MPH (2008-2009)
The University of Texas MD Anderson Cancer Center
Specialty Preferences: Cancer prevention; GI oncology; cancer screening

Daniel F. Hayes, MD (2010)
University of Michigan Comprehensive Cancer Center
Specialty Preferences: Breast cancer; clinical trials; new therapies and tumor markers; translational and clinical studies of breast

Daniel F. Heitjan, PhD (2004-2007)
Abramson Cancer Center
University of Pennsylvania
Specialty Preferences: Biostatistics; quality of life; clinical trials; health economics

Glenn Heller, PhD (2002- 2003)
Memorial Sloan Kettering Cancer Center
Specialty Preferences: Memorial Sloan Kettering Cancer Center

Roy S. Herbst, MD, PhD (1998-2000, 2007-2008)
The University of Texas MD Anderson Cancer Center
Specialty Preferences: Lung cancer; phase I trials

Kenneth R. Hess, PhD (2001-2005)
The University of Texas MD Anderson Cancer Center
Rice University
Specialty Preferences: Biostatistics

Manuel Hidalgo, MD, PhD (2005-2008)
CEU Universidad San Pablo
Centro Integral de Oncologia “Clara Campal”
Centro Nacional de Investigaciones Oncológicas
Specialty Preferences: Phase I trials; targeted agents; pharmacodynamics

Bruce J. Hillman, MD (2004-2007)
University of Virginia
Specialty Preferences: Diagnostic imaging; screening; multicenter trials

Bruce E. Hillner, MD
Virginia Commonwealth University
Specialty Preferences: Outcomes research in oncology; breast cancer

Susan G. Hilsenbeck, PhD (1998-2007)
Baylor College of Medicine
Specialty Preferences: Biostatistics; breast cancer; clinical trials; genomics and expression arrays

Waun Ki Hong, MD
The University of Texas MD Anderson Cancer Center
Specialty Preferences: Head and neck cancers; targeted therapy; chemoprevention

Ivan D. Horak, MD, FACP (2004-2007)
Enzon Pharmaceuticals, Inc.
Specialty Preferences: Antisense, siRNA, and micro RNA; monoclonal antibodies; role of biomarkers in drug development; signal transduction pathways as a target for therapy

Sandra J. Horning, MD (2005, 2010-2013)
Genentech, Inc.
Specialty Preferences: Drug development

Susan Band Horwtiz, PhD (2002)
Albert Einstein College of Medicine
Specialty Preferences: Development of drugs derived from natural products; drug resistance

S. Percy Ivy, MD (2013-2014)
National Cancer Institute
Specialty Preferences: Early drug development; clinical trial design; regulatory affairs including IND, IDE, and adverse event reporting; molecular characterization and biomarker development; experimental therapeutics: antiangiogenesis; embryonic signaling; targeted kinases; protein processing

Mary Jackson Scroggins (2012-2014)
In My Sister's Care
Specialty Preferences: Patient advocacy; gynecologic cancer

C. Carl Jaffe, MD, FACC (2004-2005)
Yale University School of Medicine
Specialty Preferences: Diagnostic radiology; nuclear medicine

Elizabeth M. Jaffee, MD (2005, 2008-2009)
Sidney Kimmel Comprehensive Cancer Center

Johns Hopkins University
Specialty Preferences: Immunotherapy; pancreatic cancer therapy; biomarker clinical development

Steven Joffe, MD, MPH (2005-2009)
Harvard Medical School
Dana-Farber Cancer Institute
Children's Hospital
Specialty Preferences: Pediatric oncology; research ethics; clinical trial design; hematopoietic stem cell transplantation

Bruce E. Johnson, MD (2008)
Dana-Farber Cancer Institute
Specialty Preferences: Targeted treatment of thoracic malignancies

David H. Johnson MD (2004)
UT Southwestern Medical Center
Specialty Preferences: Developmental therapeutics; lung cancer therapeutics

Roy B. Jones PhD, MD (2014)
MD Anderson Cancer Center
Specialty Preferences: Bone marrow transplantation (autologous/allogeneic/stem cell)

Robert L. Justice, MD
U. S. Food and Drug Administration
Specialty Preferences: Oncology drug products; drug evaluation and research

Judith E. Karp, MD (2008-2012)
Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins University
Specialty Preferences: Acute leukemias; signal transduction; cell kinetics

Kay F. Kays (2014)
Pancreatic Cancer Action Network
Specialty Preferences: GI/Pancreatic cancer; survivorship; patient advocacy; quality of life; patient accrual

M. Margaret Kemeny, MD, FACS (1996-1998, 2006)
Queens Cancer Center of Queens Hospital
Mt. Sinai School of Medicine
Specialty Preferences: GI cancers; hepatobiliary tumors; surgical oncology; cancer in the elderly

Larry G. Kessler, ScD (2010)
University of Washington School of Public Health
Specialty Preferences: Cost effectiveness and diagnostic value of medical technology in screening for cancer and other diseases

KyungMann Kim, PhD (2004-2006, 2008)
University of Wisconsin Comprehensive Cancer Center
Specialty Preferences: Developmental therapeutics; lung cancer; chemoprevention; biostatistics

Mark D. Krailo, PhD (2006-2014)
University of Southern California
Specialty Preferences: Statistical design; data collection; interim monitoring

Larry E. Kun, MD (1997, 2006-2008)
St. Jude Children's Research Hospital
The University of Tennessee College of Medicine
Specialty Preferences: Radiation oncology; neuro-oncology; pediatric oncology; late effects/pediatric cancer

Brenda F. Kurland, PhD (2012-2014)
University of Pittsburgh
Specialty Preferences: Quantitative imaging biomarkers; analysis of correlated data; early-phase cancer clinical trials

Daniel H. Laheru, MD (2010-2014)
Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins University
Specialty Preferences: Gastrointestinal oncology, specifically pancreatic and colon cancers

Kathleen R. Lamborn, PhD (2001-2003)
University of California San Francisco
Specialty Preferences: Biostatistics; glioma

Quynh-Thu Le, MD (2008)
Stanford Cancer Center
Specialty Preferences: Radiation oncology; head and neck cancers

J. Jack Lee, PhD (1998, 2000)
The University of Texas MD Anderson Cancer Ctr.
Specialty Preferences: Biostatistics; multiple biomarkers and adaptive designs to develop more efficient and ethical clinical trials

Ming Lei, PhD (2010-2011)
Center for Cancer Training
National Cancer Institute
Specialty Preferences: National management of grant-supported research training; DNA replication and chromatin assembly; training and career development of cancer scientists

Steven J. Lemery, MD (2008)
U. S. Food and Drug Administration
Specialty Preferences: Review products for gastrointestinal malignancies, melanoma, and other advanced skin cancers and sarcomas

Barbara K. LeStage, MHP (2011-2014)
Specialty Preferences: Patient advocacy; breast cancer; clinical imaging

Allen S. Lichter, MD (2007)
American Society of Clinical Oncology
Specialty Preferences: Radiation oncology

Stuart M. Lichtman, MD, FACP (2004-2005, 2007-2009)
Memorial Sloan-Kettering Cancer Center
Specialty Preferences: Gynecologic oncology; geriatric oncology

Michael P. Link, MD (2001-2003)
Stanford University School of Medicine
Specialty Preferences: Pediatric oncology; stem cell transplant

David A. Lipschitz, MD (2001-2003)
University of Arkansas for Medical Sciences
Specialty Preferences: Gerontology

Scott M. Lippman, MD (1996-2005)
The University of Texas MD Anderson Cancer Center
Specialty Preferences: Clinical and translational research: head, neck, and lung cancers; genetic drivers of cancer; predictive molecular signatures; biomarkers for clinical response in solid tumors; design of trials using molecular targets and markers for cancer prevention and therapy

Alan F. List, MD (2000-2003, 2006)
H. Lee Moffitt Cancer Center and Research Institute
University of South Florida
Specialty Preferences: Clinical studies; leukemia; myelodysplastic syndromes

John H. Littlefield, MD (2000)
The University of Texas Health Science Center at San Antonio
Specialty Preferences: Health profession education, evaluation

Albert F. Lobuglio, MD (1997)
UAB Comprehensive Cancer Center
Specialty Preferences: Immunological therapeutics

Wendy B. London, PhD (2011-2014)
Harvard University
Specialty Preferences: Neuroblastoma; prognostic stratification; clinical trial design

Patricia M. LoRusso, DO (2004-2005, 2009-2012)
Wayne State University
Karmanos Cancer Institute
Specialty Preferences: Phase I; breast cancer

Michael T. Lotze, MD (2004-2008, 2013-2014)
University of Pittsburgh
Specialty Preferences: Biologic therapy/immunobiology; gastrointestinal cancer; liver and pancreas tumors; melanoma/skin cancer

H. Kim Lyerly, MD (1997-1998)
Duke University School of Medicine
Specialty Preferences: Applied therapeutics; immunology; surgery

James C. Lynch, PhD (2001-2002, 2004-2006)
Eppley Cancer Center

University of Nebraska Medical Center
Specialty Preferences: Biostatistics; childhood cancer; clinical trials; cancer survivorship; non-Hodgkin lymphoma; stem cell transplantation

David A. Mankoff, MD, PhD (2007)
University of Washington
Specialty Preferences: Cancer imaging; breast cancer; nuclear medicine/PET; cancer biomarkers

Guido G. Marcucci, MD (2009-2010)
The Ohio State University Comprehensive Cancer Center
Specialty Preferences: Molecular biology and cancer genetics; experimental therapeutics; acute myeloid leukemia; chronic lymphocytic leukemia

Lynn M. Matrisian, PhD (2004)
Pancreatic Cancer Action Network
Specialty Preferences: Pancreatic cancer, basic science

Mary S. McCabe, RN, MA (2004-2006)
Memorial Sloan Kettering Cancer Center
Specialty Preferences: Informed consent; specimen collection; quality of life research; patient-centered endpoints

W. Gillies McKenna, MD, PhD (1998)
University of Oxford
Specialty Preferences: Radiation oncology; treatment resistance

Neal J. Meropol, MD (2007-2014)
Fox Chase Cancer Center (2007-2008)
Case Western Reserve University (2009-2014)
Specialty Preferences: Developmental therapeutics; gastrointestinal cancer; liver and pancreas tumors; medical oncology; physician-patient communication

Rosemarie Mick, MS (1997-1998, 2000, 2003)
University of Pennsylvania Perelman School of Medicine
Specialty Preferences: Biostatistics; clinical trial methodology, optimal designs for early-stage cancer trials, and the development of immunotherapies

Carol M. Moinpour, PhD (1996, 2006)
Fred Hutchinson Cancer Research Center
University of Washington
Specialty Preferences: Quality of life assessment in clinical trials; analysis issues for quality of life outcomes; clinically meaningful differences in quality of life scores; outcomes assessment in symptom management trials

Jeffrey F. Moley, MD (1996)
Washington University Siteman Cancer Center
Specialty Preferences: Endocrine and oncologic surgery; multiple endocrine neoplasia

Wayne L. Monsky, MD, PhD (1997)
University of California Davis Cancer Center
Specialty Preferences: Diagnostic and interventional radiology; minimally invasive therapies for cancer

Vicki A. Morrison, MD (2010-2014)
University of Minnesota
Specialty Preferences: Lymphoma; non-Hodgkin lymphoma; bone marrow transplantation; infectious complications in oncology patients

Heidi Nelson, MD (2001-2003)
Mayo Clinic
Specialty Preferences: Colon and rectal cancer surgery

Donna S. Neuberg, ScD (2004-2006)
Harvard School of Public Health
Dana-Farber Cancer Institute
Specialty Preferences: Statistical design and analysis; pediatrics; vaccines/immunotherapy; leukemia and lymphoma

Donna Niedzwiecki, PhD (2001)
Duke University Medical Center
Specialty Preferences: Biostatistics, clinical trials design, GI cancer, lymphoma, melanoma

Daniel P. Normolle, PhD (2008-2010)
University of Pittsburgh Cancer Institute
Specialty Preferences: Translational research design; phase I clinical trial design; biomarker analysis

Larry Norton, MD (2001)
Mayo Clinic
Specialty Preferences: Breast cancer prevention, diagnosis, and treatment

Allen Oliff, MD (1997)
GlaxoSmithKline
Specialty Preferences: Drug discovery; molecular pathogenesis: RNA tumor viruses, oncogenes, and tumor suppressor genes

Katherine S. Panageas, DrPH (2011-2014)
Memorial Sloan Kettering Cancer Center
Specialty Preferences: Clinical trial design, melanoma; immunotherapy; neuro-oncology

William Pao, MD (2012)
Vanderbilt University Ingram Cancer Center
Specialty Preferences: Translational research; lung cancer; mechanisms of sensitivity and resistance to targeted agents in solid tumors

David R. Parkinson, MD (2000-2003)
ESSA Pharma, Inc.
Specialty Preferences: Oncology drug development

Electra D. Paskett, PhD (2004)
The Ohio State University Comprehensive Cancer Center
Specialty Preferences: Epidemiology and cancer health disparities; breast cancer; colorectal cancer; uterine, cervical, and endometrial cancers

Jyoti D. Patel, MD (2013-2014)
Northwestern University
Specialty Preferences: Lung cancer

Richard Pazdur, MD (2001-2002)
U. S. Food and Drug Administration
Specialty Preferences: Oncology product regulation and clinical review

Edith A. Perez, MD (2003-2006, 2009-2014)
Mayo Clinic
Specialty Preferences: Breast cancer; targeted therapies; translational clinical trials

Jane Perlmutter, PhD (2006-2010)
Gemini Group
Specialty Preferences: Patient advocates in research; innovative trial design–Bayesian approaches and adaptive trials; improving patient communication and decision making, especially the informed consent process; biomarkers in breast cancer

Gina R. Petroni, PhD (1996-2003, 2005)
University of Virginia Cancer Center
Specialty Preferences: Design and analysis of clinical trials; data and safety monitoring; vaccine trials

Steven Piantadosi, MD, PhD (1996,1998)
Cedars-Sinai Medical Center
Specialty Preferences: Biostatistics; multi-center and international trials; innovative clinical trial methods

Tatiana M. Prowell, MD (2014)
U. S. Food and Drug Administration
Johns Hopkins University Cancer Center
Specialty Preferences: Breast cancer; general oncology

Alfred W. Rademaker, PhD (2006-2014)
Northwestern University
Specialty Preferences: Early-phase cancer clinical trial designs; sample size determination; statistical methods for diagnostic testing; cluster randomized clinical trials

Gregory H. Reaman, MD (2009-2010)
Children's Oncology Group
Specialty Preferences: Pediatric phase I and II trials; clinical trials in childhood leukemia; correlative biomarkers in pediatric cancer clinical trials

Michael P. Redden, JD, (2008-2009)
Duke Clinical Research Institute
Specialty Preferences: Patient advocacy; quality of life issues; informed consent language

Meredith M. Regan, ScD (2008-2014)
Dana-Farber Cancer Institute
Specialty Preferences: Biostatistics, particularly as applied in breast and genitourinary cancers

Brian I. Rini, MD, FACP (2011-2014)
Case Western Reserve University

Specialty Preferences: Genitourinary malignancies; renal cell carcinoma; antiangiogenic therapy; immunotherapy

Paula K. Roberson, PhD (2001)
University of Arkansas for Medical Sciences
Specialty Preferences: Design and analysis of clinical trials; variable selection; nonparametric methods

Lorna Rodrìguez-Rodrìguez, MD, PhD (2001-2006)
The Cancer Institute of New Jersey
University of Medicine and Dentistry of New Jersey
Robert Wood Johnson Medical School
Specialty Preferences: Gynecologic oncology; laboratory correlates; multimodality trials

Denise Roe, PhD (2000-2003)
University of Arizona Cancer Center
Specialty Preferences: Biostatistics and epidemiology; developing and evaluating statistical methods useful in clinical trials; prevention studies; pharmacokinetics; longitudinal studies

Stan Rosenfeld (2000)
University of California San Francisco
Specialty Preferences: Prostate cancer patient advocacy

David Rosenthal, MD (2000)
The University of Texas MD Anderson Cancer Center
Specialty Preferences: Radiation oncology; head and neck cancers

Mace L. Rothenberg, MD (2000- 2004)
Pfizer, Inc.
Specialty Preferences: Oncology drug safety and regulation

Erkki Ruoslahti, MD, PhD (1998)
Sanford-Burnham Medical Research Institute
Specialty Preferences: Targeted therapy; breast cancer and glioblastoma

John H. Sampson, MD (1998)
Duke University Medical Center
Specialty Preferences: Brain cancer; neurosurgery

Howard M. Sandler, MD (2008-2009)
Samuel Oschin Comprehensive Cancer Institute
Cedars-Sinai Medical Center
Specialty Preferences: Prostate cancer; brain tumors; bladder cancer; radiation oncology

Richard L. Schilsky, MD (2002-2006)
The University of Chicago Pritzker School of Medicine
Specialty Preferences: GI cancer; clinical trial endpoints/drug approval process; phase I trials; pharmacology; cooperative groups

Lowell E. Schnipper, MD (2007-2009)
Harvard Medical School
Beth Israel Deaconess Medical Center

Specialty Preferences: Breast cancer clinical trials; non-Hodgkin lymphoma; experimental therapeutics; drug resistance

Gary K. Schwartz, MD (2010)
Memorial Sloan Kettering Cancer Center
Weill Cornell Medical College
Specialty Preferences: Sarcoma; melanoma; new drug development

Karl L. Schwartz, MFA (2011-2014)
Patients Against Lymphoma
Specialty Preferences: Clinical trial accrual challenges – how patients see trials; eligibility criteria as they relate to enrollment and generalizability of trial results; simplifying the informed consent document; improving readability; biospecimen samples anticipating obstacles to consent

Mary J. Scroggins, MA (2006-2007, 2009-2014)
In My Sister's Care
Specialty Preferences: Health disparities; community partnerships; vulnerable populations; informed consent; quality of life; international health

Lalitha K. Shankar, MD, PhD (2005)
Cancer Imaging Program
National Cancer Institute
Specialty Preferences: Functional and molecular imaging-diagnosis and treatment of cancer; clinical trial establishment and monitoring to evaluate imaging tracers and techniques to improve prevention, diagnosis, and treatment of cancer

Westley Sholes, MPA (2008-2012)
California Prostate Cancer Coalition
Specialty Preferences: Patient advocacy issues; health care management; prostate cancer

Yu Shyr, PhD (2004-2014)
Vanderbilt University
Specialty Preferences: Biostatistics; bioinformatics; clinical trial design

Rache M. Simmons, MD, FACS (2004-2005, 2010)
Joan and Sanford Weill Medical College of Cornell University
New York Presbyterian Hospital
Specialty Preferences: Oncoplastic surgery; breast cancer surgery

Lillian L. Siu, MD, FRPCPC (1998-1999, 2003-2007)
Princess Margaret Hospital
University of Toronto
Specialty Preferences: Head and neck cancer; targeted agents; GI cancer

George W. Sledge, Jr., MD (2011-2014)
Stanford University Cancer Center
Specialty Preferences: Breast cancer; novel biologic therapies; angiogenesis and antiangiogenic therapy

Franklin O. Smith, III, MD (2011-2014)
University of Cincinnati

Specialty Preferences: Hematology/oncology; pediatric oncology; hematopoietic stem cell transplantation; acute myeloid leukemia; Fanconi anemia

Anil K. Sood, MD (2009-2014)
The University of Texas MD Anderson Cancer Center
Specialty Preferences: Gynecologic oncology; novel therapeutics; angiogenesis

Barry E. Storer, PhD (2001-2005)
University of Washington
Fred Hutchinson Cancer Research Center
Specialty Preferences: Clinical trial design; statistical method development to identify the impact of the disease incidence and therapy outcomes

Ellen L. Stovall (2002, 2004-2005)
National Coalition for Cancer Survivorship
Specialty Preferences: Patient advocacy

Steven Stratton, MD (2005-1009, 2011-2013)
University of Arizona Cancer Center
Specialty Preferences: Skin cancers; early detection; cancer interception; chemoprevention

Daniel C. Sullivan, MD (2003-2004)
Duke University Comprehensive Cancer Center
Specialty Preferences: Radiation oncology; clinical evaluation and validation of imaging biomarkers

Vera J. Suman, PhD (2004-2010)
Mayo Foundation
Specialty Preferences: Biostatistics; clinical trial design; immunologic endpoints; data safety monitoring plans/boards; surrogate endpoints; biomarkers—evaluation of prognostic value

Sandra M. Swain, MD (2012)
Washington Cancer Institute
Specialty Preferences: Targeted therapeutics for metastatic and inflammatory breast cancer

G. Marie Swanson, PhD (1996-1997)
Indiana Univ. School of Medicine
Specialty Preferences: Epidemiology; population diversity in cancer risk; breast cancer

Alphonse G. Taghian, MD, PhD (2010)
Harvard Medical School
Massachusetts General Hospital
Specialty Preferences: Radiation biology; breast radiation oncology; lymphedema; cardiac exposure to radiation

Chris H. Takimoto, MD, PhD (2014)
Janssen Research and Development
Specialty Preferences: Pharmaceutical/drug development; gastrointestinal cancer

Ian F. Tannock, MD, PhD (1996-1998, 1999-2000, 2002-2003)
University of Toronto University Health Network

Specialty Preferences: Breast, head and neck, kidney, prostate, and urinary bladder cancers; microenvironmental causes of resistance to drugs

Lisa L. Taylor, MBA (2011-2014)
NRG Oncology
Specialty Preferences: Uterine cancer; cervical cancer; ovarian cancer; prostate cancer

Margaret Tempero, MD (1998)
University of California San Francisco Pancreas Center
Specialty Preferences: Investigational therapeutics; antibody-based therapies; pancreatic cancer

Joel E. Tepper, MD (2001-2006)
University of North Carolina School of Medicine
Specialty Preferences: GI cancers; soft tissue sarcomas; radiation oncology; combined modality therapies

Charles Richard Thomas, Jr., MD (2009-2012)
The Oregon Health & Science University
Specialty Preferences: Radiation oncology with a thoracic focus; radiation oncology with a GI focus

Andrea B. Troxel, ScD (2013-2014)
University of Pennsylvania
Specialty Preferences: Longitudinal studies; missing data; quality of life; oncology

Donald L. Trump, MD (2004-2005)
Roswell Park Cancer Institute
State University of New York
Specialty Preferences: Genitourinary cancer; prostate and bladder cancer; drug discovery; biomarker development; clinical genomics and clinical cancer trials

Miguel A. Villalona-Calero, MD (2008-2011)
The Ohio State University College of Medicine and Public Health
Arthur James Cancer Hospital
Specialty Preferences: Phase I trials; EGFR pathway; lung cancer; DNA repair

Daniel D. Von Hoff, MD (1996-1999, 2003-2004, 2005-2007, 2009, 2013-2014)
Translational Genomics Institute (TGen)
Specialty Preferences: Clinical trials; biostatistics; epidemiology; liver and pancreas tumors; pharmaceutical/drug development

Jamie H. Von Roenn, MD (2010-2014)
American Society of Clinical Oncology
Specialty Preferences: Palliative care; chemotherapy; symptom management

Julie M. Vose, MD, MBA (1997)
University of Nebraska Medical Center
Specialty Preferences: Clinical trials in leukemias and lymphomas

Nu Viet Vu, PhD (2001-2003, 2005-2014)
University of Geneva
Specialty Preferences: Educational testing and evaluation; development of clinical knowledge; assessment of clinical reasoning and competence; program evaluation

Richard L. Wahl, MD (2008-2010)
Johns Hopkins Medical Institutions
Specialty Preferences: Radiology; PET; imaging

Vivian K. Weinberg, PhD (2007-2014)
University of California San Francisco
Specialty Preferences: Biostatistics; clinical trials; prostate cancer; other GU cancers; survival analysis

Louis M. Weiner, MD (1998-2000, 2003-2009)
Fox Chase Cancer Center
Temple University School of Medicine
Specialty Preferences: Immunotherapy; career development; gastrointestinal cancer

Heidi L. Weiss, PhD (2007-2012)
Baylor College of Medicine
Specialty Preferences: Biostatistics; design and analysis of cancer immunotherapy trials; design and analysis of cancer chemoprevention trials

H. Samuel Wieand, PhD (2006)
NSABP Biostatistical Center
Specialty Preferences: Biostatistics; breast and bowel cancers

Jonathan S. Wiest, PhD (2012-2013)
National Cancer Institute
Specialty Preferences: Lung cancer; cancer genetics

George T. Wilding, MD (1997-1998)
University of Wisconsin Carbone Cancer Center
Specialty Preferences: Genitourinary cancers; clinical trials

Christopher G. Willett, MD (2013-2014)
Duke University Cancer Center
Specialty Preferences: Radiation oncology; multimodality management of GI cancer; clinical trials in GI cancer

James E. Williams (2007)
Intercultural Cancer Council
Specialty Preferences: Patient advocacy; prostate cancer; cancer disparities research; prevention research

Terence Z. Wong, MD, PhD (2013-2014)
University of North Carolina
Specialty Preferences: Oncologic imaging; PET/CT; image processing; radiation therapy treatment planning; radionuclide therapy

Donn C. Young, PhD (2004-2009)
The Ohio University Comprehensive Cancer Center Biostatistics Core
Specialty Preferences: Biostatistics; clinical endpoints/quality of life; phase I/II clinical trials

S5: Thomas Reuters Report (Authors refer to provided attached PDF).